What's in ADARx Pharmaceuticals, Inc.'s pipeline?

ADARx Pharmaceuticals, Inc. has 8 drugs in our index: 0 marketed, 0 filed, 3 in Phase 3, 3 in Phase 2, 2 in Phase 1.

Which companies overlap with ADARx Pharmaceuticals, Inc.'s portfolio?

Top competitors by shared drug class: Astellas Pharma Europe B.V..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/adarx-pharmaceuticals-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

ADARx Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief

ADARx Pharmaceuticals, Inc. pipeline: 0 marketed, 0 filed, 3 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 3 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
ADX-324	ADX-324	phase 3	ADAR activator	ADAR1/ADAR2	Genetic/Rare Disease
ADX-324 Dose Level 1	ADX-324 Dose Level 1	phase 3	ADAR inhibitor	ADAR1 and/or ADAR2	Immunology / Autoimmune
ADX-324 Dose Level 2	ADX-324 Dose Level 2	phase 3	ADAR1 inhibitor	ADAR1 (Adenosine Deaminase Acting on RNA 1)	Oncology

Therapeutic area mix

Oncology · 2
Genetic/Rare Disease · 1
Immunology · 1
Immunology / Autoimmune · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Astellas Pharma Europe B.V. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for ADARx Pharmaceuticals, Inc.:

Cite this brief

Drug Landscape (2026). ADARx Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/adarx-pharmaceuticals-inc. Accessed 2026-05-16.